18 Jul anti-PDI mAb pembrolizumab
Merck has recently opened several clinical trials using the anti-PDI mAb pembrolizumab which may be of interest for individuals who have developed advanced stage cancers. These trials are enrolling patients with tumors that are microsatellite instability-high (MSI-H). For those with advanced stage MSI-H colorectal cancer (cancer of the colon or rectum), KEYNOTE-164 (ClinicalTriaIs.gov Identifier NCT02460198) is evaluating pembrolizumab in patients who have failed prior therapy, while KEYNOTE-177 (NCT02563002) is evaluating pembrolizumab treatment in the first line setting. For patients with advanced stage MSI-H cancers that are not of colonic or rectal origin, KEYNOTE-158 (NCT02628067) is evaluating pembrolizumab as therapy in those who have failed prior treatment. For more details and contact information on any of these trials, please visit www.keynoteclinicaltrials.com/trials or www.clinicaltrials.gov.